Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients

Autor: Robert A. Wolff, Ching Wei D. Tzeng, Michael J. Overman, Chirayu Mohindroo, Shubham Pant, Milind Javle, Wenli Dong, Gauri R. Varadhachary, Michael T. Lotze, Matthew H.G. Katz, Merve Hasanov, David R. Fogelman, Seyda Baydogan, Jane E. Rogers, Florencia McAllister, Michael P. Kim, Jonathan D. Mizrahi, Laura R. Prakash
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
Cancer Research
Multivariate analysis
Time Factors
medicine.medical_treatment
Antibiotics
Gastroenterology
Deoxycytidine
antibiotics
Research Articles
RC254-282
Aged
80 and over
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Bacterial Infections
Middle Aged
Chemotherapy regimen
Progression-Free Survival
Anti-Bacterial Agents
Treatment Outcome
Oncology
Cohort
Adenocarcinoma
Female
Fluorouracil
medicine.drug
Carcinoma
Pancreatic Ductal
Research Article
Adult
medicine.medical_specialty
autophagy
medicine.drug_class
Antineoplastic Agents
chemotherapeutic agents
Internal medicine
medicine
microbiota
pancreatic adenocarcinoma
Humans
Radiology
Nuclear Medicine and imaging
Aged
Retrospective Studies
Chemotherapy
business.industry
Cancer
Clinical Cancer Research
medicine.disease
Gemcitabine
immunity
Gastrointestinal Microbiome
Pancreatic Neoplasms
Multivariate Analysis
business
Epidemiologic Methods
Zdroj: Cancer Medicine, Vol 10, Iss 15, Pp 5041-5050 (2021)
Cancer Medicine
ISSN: 2045-7634
Popis: Recent studies defined a potentially important role of the microbiome in modulating pancreatic ductal adenocarcinoma (PDAC) and responses to therapies. We hypothesized that antibiotic usage may predict outcomes in patients with PDAC. We retrospectively analyzed clinical data of patients with resectable or metastatic PDAC seen at MD Anderson Cancer from 2003 to 2017. Demographic, chemotherapy regimen and antibiotic use, duration, type, and reason for indication were recorded. A total of 580 patients with PDAC were studied, 342 resected and 238 metastatic patients, selected retrospectively from our database. Antibiotic use, for longer than 48 hrs, was detected in 209 resected patients (61%) and 195 metastatic ones (62%). On resectable patients, we did not find differences in overall survival (OS) or progression‐free survival (PFS), based on antibiotic intake. However, in the metastatic cohort, antibiotic consumption was associated with a significantly longer OS (13.3 months vs. 9.0 months, HR 0.48, 95% CI 0.34–0.7, p = 0.0001) and PFS (4.4 months vs. 2 months, HR 0.48, 95% CI 0.34–0.68, p =
We have analyzed the effect of antibiotics’ intake on two cohorts of patients with pancreatic adenocarcinoma, resectable, and metastatic. We have found that on the metastatic cohort, antibiotics use was significantly associated with better outcomes, particularly, on patients that received gemcitabine based‐chemotherapy as the first line.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje